Pimecrolimus Side Effects: What to Expect and When to Call Your Doctor

Pimecrolimus (Elidel) is generally well-tolerated, but like all medications, it comes with possible side effects. Most are mild and temporary — but there's also an important FDA black box warning you should understand before starting treatment. Here's what you need to know.

The Most Common Side Effect: Burning and Stinging at the Application Site

The most frequently reported side effect of pimecrolimus is a burning, stinging, or itching sensation at the site where you apply the cream. This is especially common during the first few days of treatment and tends to be more intense when the skin is acutely inflamed (actively flaring). The good news: this sensation typically decreases or disappears with continued use as the eczema begins to improve.

Tips to minimize burning and stinging:

Make sure the skin is dry before applying — don't apply to wet skin immediately after bathing

Apply a thin layer — using more doesn't help and may increase side effects

Some clinicians pre-treat with a topical steroid briefly to reduce acute inflammation before switching to pimecrolimus, which can reduce initial burning

Other Common Side Effects

Skin redness (erythema): Temporary redness at the application site, usually in the first week

Viral skin infections: Pimecrolimus reduces local immune response, which can increase susceptibility to viral infections at the treated site. Cold sores (herpes simplex), chickenpox, and shingles (varicella-zoster virus) may occur more easily on treated skin.

Alcohol flush reaction: Drinking alcohol while using pimecrolimus may cause warmth, flushing, or redness in the skin or face. This is a known interaction.

Folliculitis: Inflammation of hair follicles can occasionally occur at application sites.

Sun sensitivity: Pimecrolimus can increase skin sensitivity to UV light. Avoid sun lamps, tanning beds, and prolonged sun exposure during treatment. Wear protective clothing and apply sunscreen to treated areas.

The FDA Black Box Warning: Understanding the Cancer Risk

In January 2006, the FDA required pimecrolimus to carry a black box warning — the most serious type of warning on a drug label — noting that in rare cases, patients using topical calcineurin inhibitors (pimecrolimus and tacrolimus) had developed lymphoma or skin cancer. The FDA considered this a potential theoretical risk based on animal studies and the drug's mechanism of action.

However, here's what clinical evidence has shown since:

A 2023 systematic review and meta-analysis published in The Lancet Child & Adolescent Health found no increased risk of cancer with topical calcineurin inhibitor use (moderate-certainty evidence)

Post-marketing surveillance data has not established a causal link between pimecrolimus and lymphoma or skin cancer

The American Academy of Dermatology and the American Academy of Allergy, Asthma, and Immunology have both protested the inclusion of the warning, citing lack of causal evidence

The warning remains on the label as of 2026 despite this evidence. Always discuss your individual risk with your doctor, especially if you have a personal or family history of skin cancer or lymphoma.

Serious Side Effects: When to Call Your Doctor Immediately

Signs of severe allergic reaction: Hives, swelling of the face or throat, difficulty breathing — stop use immediately and seek emergency care

Eczema herpeticum: A serious infection where herpes simplex virus spreads widely over eczema-affected skin. Signs include painful blisters, fever, and flu-like symptoms. This requires urgent medical attention.

Widespread skin infection: Stop pimecrolimus if a bacterial or viral skin infection develops in the treated area. Do not apply pimecrolimus to infected skin.

No improvement after 6 weeks: If your eczema symptoms have not improved after 6 weeks of twice-daily use, call your doctor. You may need a different treatment or a re-evaluation of your diagnosis.

Side Effects Pimecrolimus Does NOT Cause (Key Advantage)

One of pimecrolimus's most important advantages over topical corticosteroids is that it does NOT cause:

Skin atrophy (thinning): Prolonged steroid use on thin skin areas (face, eyelids, skin folds) can cause skin thinning. Pimecrolimus does not have this effect.

Striae (stretch marks): Another steroid complication not associated with pimecrolimus

HPA axis suppression: Significant systemic absorption is minimal with pimecrolimus, even when applied to large body surface areas in children

For important information about what medications and substances to avoid while using pimecrolimus, see our pimecrolimus drug interactions guide.